Cellectis ( Cellectis )

Cellectis

Cellectis's picture

About Cellectis

Cellectis a biopharmaceutical company focused on developing immunotherapies based on genome-edited CAR T-cells (UCARTs).[1] Cellectis was founded in 1999 and designs novel products including immune therapies for cancer and enzymes which can add DNA at targeted places in genomes.

Cellectis press release, blog etc

09/18/2018 - 22:37 CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board
09/18/2018 - 09:56 Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP
08/21/2018 - 21:08 Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO
08/02/2018 - 09:17 Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer
06/25/2018 - 23:57 Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018
06/11/2018 - 20:26 Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports
06/04/2018 - 12:52 FDA Grants Cellectis IND Approval for UCART22 in B-ALL
05/22/2018 - 13:14 Calyxt Announces Successful Closing of $60.9 Million Public Offering
05/22/2018 - 11:18 Approval of UCART123 Amendment in AML to Accelerate Clinical Development
05/21/2018 - 03:35 Calyxt Announces Full Exercise of Underwriters Option to Purchase Additional Shares
05/18/2018 - 05:04 Calyxt Announces Upsizing and Pricing of Follow-On Offering
05/15/2018 - 14:34 Calyxt Announces Launch of Proposed Follow-On Offering
05/10/2018 - 13:32 Cellectis to Present Data at the 2018 ASGCT Annual Meeting
05/02/2018 - 16:57 Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)
05/01/2018 - 06:09 Harvards Wyss Institute partners with Cellectis to recode the human genome
04/10/2018 - 23:30 Cellectis to Present Data at the 2018 AACR Annual Meeting
04/10/2018 - 16:51 Cellectis Announces Closing of Follow-On Offering
04/09/2018 - 09:19 Allogene Therapeutics Completes Agreement for Pfizers Allogeneic CAR T Immuno-oncology Portfolio